Regulatory approval

Published by the European Medicines Agency. Approved

KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

This is written in the approval document.

Citation

Mirati Therapeutics B.V. Krazati (adagrasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2024-01-05	European Medicines Agency	Indication received approval from the European Commission.